A study looking at what helps, and what makes it harder, for women with primary breast cancer to take CDK4/6 inhibitor treatment as prescribed.
What’s the title of the study?
SWEET-PLUS: Supporting adherence to adjuvant CDK4/6 inhibitors in women with early breast cancer
What’s the study about?
The SWEET-PLUS study aims to understand what helps, and what makes it difficult, for women with primary breast cancer who are prescribed CDK4/6 inhibitors (abemaciclib or ribociclib) to keep taking them as recommended.
The team will gather information through interviews with women from Black African and Black Caribbean communities. They’ll then use what they learn to create a support tool, developed in collaboration with people living with breast cancer. They hope that in doing so they can help women feel more supported to take their treatment as prescribed.
Who’s organising it?
Name of project lead: Professor Linda Sharp (project lead) and Dr Pearlin Teow (recruitment contact)
Job title: Research Associate
Organisation: Newcastle University
Email address: pearlin.teow@ncl.ac.uk
Phone number: 07548 558660
Who can take part?
- You can take part if you:
- Are a Black African or Black Caribbean woman
- Have been prescribed a CDK4/6 inhibitor (abemaciclib or ribociclib) after a primary breast cancer diagnosis
The researchers want to hear from a wide range of views. You can take part whether you are currently taking the medication, have stopped temporarily, have stopped completely, or are changing dosages.
Why do you want me to be involved?
Black African and Caribbean women are historically under-represented in research.
By taking part, you can help the researchers better understand what it is really like to take CDK4/6 inhibitors. This includes side effects, practical challenges, and impacts on everyday life.
Your experiences will directly shape the development of a support tool that could help other women on these medicines in the future.
What will you ask me to do?
You’ll be invited to take part in a 30-45 minute conversation about your experiences with CDK4/6 inhibitors. This can take place online, by phone, or in person, at a time that suits you, including evenings or weekends.
You’ll be asked about your experiences of taking the medication, but there are no right or wrong answers. You can skip any questions you don’t want to answer, and you can stop at any time. The interview will be audio-recorded and typed up afterwards.
And as a thank you for your time, you’ll receive a £25 shopping voucher after the interview.
If you’re interested, you may also be invited to help co-design and test a new support tool in later stages of the research, but this is entirely optional.
How do I get involved?
If you’re interesting in taking part, please complete the expression of interest form.
Or if you’d like some more information before you decide whether you would like to take part, please contact the recruitment contact Dr Pearlin Teow via email at pearlin.teow@ncl.ac.uk or call 07548 558 660
When’s the deadline?
This study is ongoing
Get involved
Share your experience of with CDK4/6 inhibitors and help researchers develop a tool to support women to better manage their treatment in the future.